Determining the coverage and efficacy of the COVID-19 vaccination program at the community level in children aged 12 to 17 in Tehran.

IF 1.7 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

GMS Hygiene and Infection Control Pub Date : 2024-01-30 eCollection Date: 2024-01-01 DOI:10.3205/dgkh000459

Sedigheh Rafiei Tabatabaei, Delara Babaie, Seyedeh Mahsan Hoseini-Alfatemi, Ahmadreza Shamshiri, Abdollah Karimi

{"title":"Determining the coverage and efficacy of the COVID-19 vaccination program at the community level in children aged 12 to 17 in Tehran.","authors":"Sedigheh Rafiei Tabatabaei, Delara Babaie, Seyedeh Mahsan Hoseini-Alfatemi, Ahmadreza Shamshiri, Abdollah Karimi","doi":"10.3205/dgkh000459","DOIUrl":null,"url":null,"abstract":"Background: The vaccination is one of the acceptable and recomended solution to prevent and control of COVID-19. The aim of this study was to determine the efficacy of sinopharm vaccination in children aged 12-17 in Tehran.Methods: The case population study was performed from October 2021 to March 2022 among 1,500 children with positive PCR test reffered in Mofid Children's Hospital in Tehran. 64 children aged 12-17 years were included. The data were collected by the hospital information system (HIS), vaccination information registration systems and questionnaire with their families. The coverage and efficacy of vaccination determined with equels commented by WHO.Results: Out of 64 children, 52 children were 12 to 15 years old (13.35±1.08), 12 children were 16 to 17 years old (16.55±0.52). 48.4% had received two doses of vaccine. The highest rate of positive PCR was observed in February 2022. Sinopharm vaccine coverage in this age group was 93.6% for the first dose and 81.1% for the second dose. Based on this information, 48.4% children in this study have received two complete doses of the COVID-19 vaccine. The efficacy of the vaccine was estimated as 94.4% (95% CI 90.2 to 97.7).Conclusion: It seems the coverage of Sinopharm vaccination in the age group of 12-17 years in Tehran is favorable and has high efficacy in this age group. In order to obtain more accurate and comprehensive estimation, it is recommended to take a sample on a wider level of the community.","PeriodicalId":12738,"journal":{"name":"GMS Hygiene and Infection Control","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10884833/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GMS Hygiene and Infection Control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3205/dgkh000459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The vaccination is one of the acceptable and recomended solution to prevent and control of COVID-19. The aim of this study was to determine the efficacy of sinopharm vaccination in children aged 12-17 in Tehran.

Methods: The case population study was performed from October 2021 to March 2022 among 1,500 children with positive PCR test reffered in Mofid Children's Hospital in Tehran. 64 children aged 12-17 years were included. The data were collected by the hospital information system (HIS), vaccination information registration systems and questionnaire with their families. The coverage and efficacy of vaccination determined with equels commented by WHO.

Results: Out of 64 children, 52 children were 12 to 15 years old (13.35±1.08), 12 children were 16 to 17 years old (16.55±0.52). 48.4% had received two doses of vaccine. The highest rate of positive PCR was observed in February 2022. Sinopharm vaccine coverage in this age group was 93.6% for the first dose and 81.1% for the second dose. Based on this information, 48.4% children in this study have received two complete doses of the COVID-19 vaccine. The efficacy of the vaccine was estimated as 94.4% (95% CI 90.2 to 97.7).

Conclusion: It seems the coverage of Sinopharm vaccination in the age group of 12-17 years in Tehran is favorable and has high efficacy in this age group. In order to obtain more accurate and comprehensive estimation, it is recommended to take a sample on a wider level of the community.

查看原文本刊更多论文

确定 COVID-19 疫苗接种计划在德黑兰 12 至 17 岁儿童中的社区覆盖率和有效性。

背景：接种疫苗是预防和控制 COVID-19 的可接受和推荐的解决方案之一。本研究的目的是确定在德黑兰 12-17 岁儿童中接种希诺福疫苗的效果：病例研究于 2021 年 10 月至 2022 年 3 月在德黑兰莫菲德儿童医院的 1500 名 PCR 检测呈阳性的儿童中进行。其中包括 64 名 12-17 岁的儿童。数据通过医院信息系统（HIS）、疫苗接种信息登记系统和对其家人的问卷调查收集。疫苗接种的覆盖率和有效性由世界卫生组织（WHO）评定：在 64 名儿童中，52 名儿童为 12-15 岁（13.35±1.08），12 名儿童为 16-17 岁（16.55±0.52）。48.4%的儿童接种过两剂疫苗。2022 年 2 月的 PCR 阳性率最高。该年龄组的国药疫苗接种率为：第一剂 93.6%，第二剂 81.1%。根据这一信息，本研究中有 48.4% 的儿童接种了两剂完整的 COVID-19 疫苗。疫苗效价估计为 94.4%（95% CI 90.2 至 97.7）：看来，国药疫苗在德黑兰 12-17 岁年龄组的接种覆盖率很高，并且在该年龄组具有很高的效力。为了获得更准确、更全面的估计，建议在更广泛的社区进行抽样调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

GMS Hygiene and Infection Control PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

自引率

0.00%

发文量

审稿时长

10 weeks